Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs
- 6 November 1998
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 282 (5391) , 1072-1074
- https://doi.org/10.1126/science.282.5391.1072
Abstract
The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery—such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.This publication has 26 references indexed in Scilit:
- MUTANT GENES IN FAMILIAL ALZHEIMER'S DISEASE AND TRANSGENIC MODELSAnnual Review of Neuroscience, 1998
- Intranuclear Neuronal Inclusions: A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases?Published by Elsevier ,1997
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Drug Delivery to the BrainJournal of Cerebral Blood Flow & Metabolism, 1997
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997
- Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs DiseaseCNS Drugs, 1996
- An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s diseaseBrain, 1996
- Amyloid beta amyloidosis in Alzheimerʼs diseaseCurrent Opinion in Neurology, 1995
- Neural Transplantation: A Call for Patience Rather Than PatientsScience, 1988
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982